News
Takeda’s dengue vaccine candidate delivers continued protection
Takeda has announced that its dengue vaccine, TAK-003, prevented 84% of hospitalised cases and 61% of symptomatic cases.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Takeda has announced that its dengue vaccine, TAK-003, prevented 84% of hospitalised cases and 61% of symptomatic cases.